Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
06 Giugno 2023 - 3:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: June 2023
Commission file number: 001-36288
Akari
Therapeutics, Plc
(Translation of registrant’s name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
On June 6, 2023, Akari Therapeutics, Plc, a public
company with limited liability incorporated under the laws of England and Wales (the “Company”), informed its shareholders
that it will hold its Annual General Meeting on June 30, 2023. In connection with the meeting, the Company furnished the following documents:
| 1. | Notice of Annual General Meeting of Shareholders and Proxy Statement dated June 6, 2023 |
| 3. | Statutory Accounts for the year ended December 31, 2022 |
The information contained in this report (including
the exhibits hereto) is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities
Act of 1933.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Akari Therapeutics, Plc |
| |
(Registrant) |
| |
|
| |
By: |
/s/ Rachelle Jacques |
| |
Name: |
Rachelle
Jacques |
| |
Title: |
President and Chief Executive Officer |
Date: June 6, 2023
Grafico Azioni Akari Therapeutics (NASDAQ:AKTX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Akari Therapeutics (NASDAQ:AKTX)
Storico
Da Mag 2023 a Mag 2024
